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Introduction
Childhood-onset systemic lupus erythematosus (cSLE) is a
more severe disease when compared to adult-onset SLE,
with higher disease activity at onset and during disease
course, higher percentage of major organ involvement and
more rapid accrual of damage. Long-term outcome studies
on cSLE are rare.
Objectives
This study aims to describe the long-term outcomes of
patients with cSLE that have reached adulthood.
Methods
All Dutch rheumatologists, immunologists, nephrologists,
haematologists, neurologists were asked to refer cSLE
patients to the CHILL-NL (CHILdhood Lupus in the
NetherLands) study team. The study was promoted in
magazines and on websites of the Dutch SLE patient
organizations. Interested adult cSLE patients were asked
to approach the study team. All patients were seen for a
single study visit. Patients’ current health status was
assessed with an extensive medical interview and physical
examination. All previous medical correspondence was
retrieved, including information regarding cumulative
multisystem involvement, auto-antibody profiles, drug
use and comorbidities. SLE disease activity index-2K
(SLEDAI-2K) and SLICC damage index (SDI) was calcu-
lated. Quality of life and related factors such as educa-
tional and work status, fecundity, fatigue and depressive
symptoms were assessed.
Results
31 patients (87% female) are currently included with a
median age at diagnosis of 13 years (range 9-18) and
median disease duration at time of visit was 15 years
(range 4 – 36). At time of visit, median SLEDAI-score
was 4 (0 – 9). 20/31 (65%) patients had an SDI-score of
at least 1 (median 1, range 0 – 7). Current medication
use included hydroxychloroquine in 63% of all patients,
prednisone in 52%. 48% of the patients were treated
with at least one DMARD (MMF (27%), Azathioprine
(25%) and others). Half of the patients ever had CNS
involvement. Two thirds of patients ever had renal
involvement. Of these patients, 33% had current protei-
nuria (>50 mg/mmol). Four (13%) patients had a renal
transplantation. During their disease course, 32% of the
patients had been hospitalised at least once due to a
severe infection. Analyses on factors related to quality of
life are pending. Table 1.
Conclusion
cSLE is associated with significant long-term conse-
quences, including frequent renal and CNS involvement,
accrual of damage in the majority of patients and almost
all patients still using DMARDs, prednisone, hydroxy-
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Table 1
Characteristic Frequency (median +
range)
Age at diagnosis 13 years (9 – 18)
Disease duration 15 years (4 – 36)
SLEDAI-score 4 (0 – 9)










Peripheral nervous system 10%
(Vertebral) fractures 23%
Severe infections (hospitalization necessary) 32%







Family history 1stdegree 2nddegree
SLE 14% 0%
other auto-immune diseases 55% 57%
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